rss
Br J Ophthalmol 2000;84:609-613 doi:10.1136/bjo.84.6.609
  • Original Article
    • Clinical science

Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study

  1. Agnès Glacet-Bernarda,
  2. Dagmar Kuhna,
  3. Andrew K Vineb,
  4. Hassiba Oubrahama,
  5. Gabriel Coscasa,
  6. Gisèle Soubranea
  1. aUniversity Eye Clinic of Créteil, University of Paris XII, Créteil, France, bWK Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA
  1. Agnès Glacet-Bernard, MD, University Eye Clinic of Créteil, 40, avenue de Verdun, 94000 Créteil, France agnes.glacet{at}chicreteil.fr
  • Accepted 28 January 2000

Abstract

AIMS To study the effects of intravitreal tissue plasminogen activator (tPA) in recent onset central retinal vein occlusion (CRVO).

METHODS 15 patients with recent onset CRVO (from 1–21 days' duration, mean 8 days) were given 75–100 μg of tPA intravitreally associate with low dose low molecular weight heparin. CRVO was perfused in nine patients and with mild ischaemia not exceeding 100 disc diameters in six patients. Follow up ranged from 5 to 21 months for 14 patients (mean 8 months). Visual acuity measurement, macular threshold (Humphrey perimeter), fluorescein angiography with the scanning laser ophthalmoscope with special emphasis on retinal circulation times, and retinal perfusion were performed at days 0, 1, and 8 and months 1, 3, and 6.

RESULTS Visual acuity was significantly improved on the first day after treatment in only one eye, and decreased transiently in six eyes (40%). Retinal blood velocity was not significantly modified by tPA injection. Retinal ischaemia developed in six eyes (43%), leading to panretinal photocoagulation in five eyes including one with rubeosis iridis. At the end of follow up, visual acuity had improved to 20/30 or better in five eyes (36%), including two with complete recovery; visual acuity was worse than 20/200 in three eyes (28%). No complication of tPA injection was observed.

CONCLUSION Intravitreal tPA treatment for CRVO appears to be simple and safe, but did not significantly modify the course of the occlusion in our patients immediately after treatment. Final visual outcome did not differ significantly from that observed in the natural course of the disease, but final visual acuity seemed to be slightly better. A randomised study is required to determine if intravitreal tPA actually improves visual outcome in CRVO.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.